Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 20/20 | 0.44 |
| ▸ | MMP10 | P09238 | 6/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | MMP8 | P22894 | 7/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL943811 | 0.96 | MMP13 (0.43) | MMP13MMP10MMP2MMP8 | |
| SCHEMBL943226 | 0.94 | MMP13 (0.44) | MMP13MMP10MMP2MMP8 | |
| SCHEMBL943356 | 0.92 | MMP13 (0.43) | MMP13MMP10MMP2MMP8 | |
| SCHEMBL943357 | 0.92 | MMP13 (0.43) | MMP13MMP10MMP2MMP8 | |
| SCHEMBL941805 | 0.92 | MMP13 (0.43) | MMP13MMP10MMP2MMP8 | |
| SCHEMBL942367 | 0.92 | MMP13 (0.46) | MMP13MMP10MMP2MMP8 | |
| SCHEMBL942615 | 0.92 | MMP13 (0.46) | MMP13MMP10MMP2MMP8 | |
| SCHEMBL944376 | 0.92 | MMP13 (0.46) | MMP13MMP10MMP2MMP8 | |
| SCHEMBL943380 | 0.91 | MMP13 (0.44) | MMP13MMP10MMP2MMP8 | |
| SCHEMBL941343 | 0.91 | MMP13 (0.46) | MMP13MMP10MMP2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009435-A1 | HETERO BICYCLIC CARBOXAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER, INC. (US) | 2011-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009435-A1 | HETERO BICYCLIC CARBOXAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | CNR2, CYP2C9, CYP2C8 | MMP13 2678/4885MMP10 3840/4885MMP2 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.